L. Franca

Influence of BMI and geographical region on prescription of oral anticoagulants in newly diagnosed atrial fibrillation: The GLORIA-AF Registry Program.

G. Lip, G. Boriani, M. Huisman, 2020, European journal of internal medicine.

Anticoagulation Prescription and Outcomes in Relation to Renal Function in Patients with Atrial Fibrillation: Results from GLORIA-AF

H. Diener, K. Rothman, J. Halperin, 2021, TH Open.

Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program.

G. Lip, H. Diener, K. Rothman, 2019, American heart journal.

Reversal strategies and outcomes in patients with atrial fibrillation and warfarin-associated intracranial hemorrhage.

D. Singer, J. Goldstein, S. Regan, 2020, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up

A. Brandes, H. Diener, K. Rothman, 2020, Journal of clinical medicine.

Claims Data Studies of Direct Oral Anticoagulants Can Achieve Balance in Important Clinical Parameters Only Observable in Electronic Health Records

K. Huybrechts, S. Schneeweiss, J. Franklin, 2018, Clinical pharmacology and therapeutics.

Preliminary study on the role of alternative educational pathways in promoting the use of problem-focused coping strategies

Christophe Genolini, J. Guelfi, C. Genolini, 2009 .

Evolution of antithrombotic therapy for patients with atrial fibrillation: The prospective global GLORIA-AF registry program

K. Rothman, J. Halperin, S. Dubner, 2022, PloS one.

PCN36 A COST UTILITY ANALYSIS OF FIRST-LINE CHEMOTHERAPY REGIMENS IN THE TREATMENT OF METASTATIC BREAST CANCERAFTERANTHRACYCLINE FAILURE

R. Launois, K. Lay, L. R. França, 2005 .

Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry Program.

G. Lip, H. Diener, K. Rothman, 2018, The American journal of medicine.

Dabigatran Persistence and Outcomes Following Discontinuation in Atrial Fibrillation Patients from the GLORIA-AF Registry.

G. Lip, H. Diener, K. Rothman, 2019, The American journal of cardiology.

Antithrombotic treatment for newly diagnosed atrial fibrillation in relation to patient age: the GLORIA-AF registry programme.

G. Lip, J. Healey, H. Diener, 2019, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

Cost-effectiveness of activated protein C in real-life clinical practice

D. Annane, J. Dhainaut, B. Guidet, 2007, Critical care.

Budget impact model of rituximab after failure of one or more TNFalpha inhibitor therapies in the treatment of rheumatoid arthritis.

R. Launois, N. Saidenberg-Kermanac’h, M. Boissier, 2008, Joint, bone, spine : revue du rhumatisme.